Mirum Pharmaceuticals Inc (MIRM)vsMerck & Company Inc (MRK)
MIRM
Mirum Pharmaceuticals Inc
$93.72
+0.19%
HEALTHCARE · Cap: $5.61B
MRK
Merck & Company Inc
$146.72
-0.14%
HEALTHCARE · Cap: $368.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 10801% more annual revenue ($67.38B vs $618.07M). MRK leads profitability with a 3.6% profit margin vs -139.2%. MRK earns a higher WallStSmart Score of 44/100 (D).
MIRM
Avoid30
out of 100
Grade: F
MRK
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+45.4%
Fair Value
$182.99
Current Price
$93.72
$89.27 discount
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$146.72
$62.06 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37.9% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
ROE of -329.4% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Trading at 8.6x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MIRM
The strongest argument for MIRM centers on Revenue Growth, Debt/Equity. Revenue growth of 37.9% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : MIRM
The primary concerns for MIRM are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
MIRM profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
MIRM carries more volatility with a beta of 0.61 — expect wider price swings.
MIRM is growing revenue faster at 37.9% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 30/100). MIRM offers better value entry with a 45.4% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mirum Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?